Napthacipiprant

萘福帕罗

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNapthacipiprant
Drug Alias NameKBP-7026
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstaglandin D2 receptor 2 antagonists
TargetsProstaglandin D2 receptor 2
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShandong Hengli Pharmaceutical Technology Co LtdKbp Biosciences Usa
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesKbp Biosciences UsaShandong Hengli Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A